While treatments for asthma and allergic disorders have improved, their burdens continue to have enormous economic consequences. The costs of allergies to the United States each year were estimated at $56 billion in 2007, a figure that includes direct medical costs and indirect productivity losses. 8 Within the European Union, the cost estimates range from €55 to €151 billion per year, including indirect costs related to absence or reduced productivity at work. 9 Severe asthmatics not controlled by medications contribute more than double the healthcare costs vs asthmatics controlled by medication. 10 Although biologic therapies have provided many patient benefits, the costs vs benefits of biologics based on certain economic analyses limit their widespread use to restricted patient populations. 11 Ideally, small molecules could be identified with different mechanisms of action than current allergic drug classes, while still delivering the same symptomatic improvements. These smallmolecule drugs might even have fewer side effects than the current mainstay drugs, particularly steroids.
| DRUG REPURPOSING
The development of new small-molecule drugs, however, is a risky undertaking costing hundreds of millions of dollars and requiring years of research and clinical trials. This includes the challenge of target discovery, validation in animal models of disease, optimizing a lead candidate's pharmacokinetic properties for oral intake, safety testing in patients, and finally, trials for efficacy against the targeted disease, which can carry high failure rates even into phase II and phase III clinical trials. 12 While the ultimate drug efficacy in these later phases will always be uncertain, many drugs initially fail during safety testing in a phase I trial, where a drug is tested in normal, healthy subjects at increasing doses and analyzed for any phenotypic changes or other abnormalities and toxicities. 12 Before entering clinical trials and phase I testing, extensive data must be presented to the Food and Drug Administration (FDA) demonstrating the safety of small molecules in mouse models, nonhuman primates, and other species, in order to get an investigational new drug (IND) application approved. This occurs after years of research necessary to identify a good lead drug candidate, which can prove challenging due to the difficulties of finding targets, performing small-molecule screens for activity, and most importantly, reproducing data across laboratories and experiments. 13 All these steps mark a long wait (10+ years until approval) for those with uncontrolled symptoms of disease and no other treatment options. 
| LYMPHOCYTE -MODULATIN G AGENTS
Among the signaling molecules crucial for T cell activation, the janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway plays a crucial role. JAK/STAT is downstream of many important cytokine receptors that augment T cell activation. 26 As a result, a number of different JAK and STAT inhibitors have been developed that might dampen T cell activation. An example is tofacitinib, an inhibitor to both JAK1 and JAK3, and currently approved for the treatment of rheumatoid arthritis. 27 Tofacitinib has also shown efficacy in a phase II trial to treat ankylosing spondylitis, improving severity and symptoms vs placebo after 12 weeks. 28 Moving into allergic diseases, tofacitinib has been explored to treat atopic dermatitis (AD). The rationale was that T cells are also crucial to the inflammation in atopy, a chronic state with unclear environmental triggers. Tofacitinib therapy yielded antipruritic and anti-inflammatory responses in a mouse model of allergic dermatitis when applied topically. 29 Extending into patients, oral tofacitinib in a clinical trial to treat recalcitrant AD found a significant decline in AD severity score. 30 Exploring a different dermatological disease, tofacitinib was also tested for the treatment of psoriasis in phase II clinical trials. 31 Psoriasis is an autoimmune disease of the skin driven by T cells, and clinical trial results suggested positive benefits for tofacitinib in this disease as well. 31 Given the similarities of these diseases to allergic inflammation, it can easily be imagined that tofacitinib could find efficacy in pilot clinical studies.
Another small molecule in this class is ruxolitinib, which is a JAK1/2 inhibitor having a slightly different selectivity than tofacitinib. Ruxolitinib is currently approved for the treatment of intermediate-or high-risk myelofibrosis, and for polycythemia vera in patients who do not respond to hydroxyurea treatment. 32 Ruxolitinib has been found to potently suppress T cell functions in vitro and in myelofibrosis patients, inhibiting IL-2-dependent STAT5 activation and resultant pro-inflammatory cytokine secretion. 33 Ruxolitinib has also shown promise in case reports in treating recalcitrant dermatomyositis 34 and chilblain lupus erythematosus, 35 suggesting potential use in immunomodulation for other disorders. Extending into allergy, ruxolitinib was studied for repurposing to treat food allergies, which is driven in part by T cell effectors in the gut. Oral administration of ruxolitinib into a food allergy mouse model found marked remission of symptoms. 36 The finding has yet to be extended to humans, but demonstrates that JAK/STAT pathway inhibitors may be exciting candidates for the treatment of allergic disorders.
Pathogenic T cells can also be modulated by targeting interleukin-2-inducible T cell kinase (ITK), which functions in promoting Th2 differentiation. 37 A small molecule, ibrutinib, has been developed that inhibits ITK and Th2 immunity, while sparing Th1 immunity. 38 Ibrutinib also inhibits Bruton's tyrosine kinase (BTK), having efficacy in the treatment for B cell malignancies, where it holds FDA approval. Beyond cancer, BTK inhibitors also suppress normal B cell receptor signaling, which was used in animal models to successfully suppress autoantibody production and the development of collageninduced arthritis and lupus nephritis, respectively. 39 Furthermore, ibrutinib can improve symptoms in different autoimmune arthritis mouse models, both those that are dependent on autoantibody production, and surprisingly, in those models that do not. 40 This indicates that beyond B cells, monocytes, macrophages, and mast cells may be inhibited by ibrutinib, thereby improving arthritic conditions. 40 Treating allergic disease, IgE-mediated signaling and activation in human basophils was inhibited in vitro by ibrutinib. 41 In a pilot study of patients already on ibrutinib for an underlying lymphoid malignancy, ibrutinib was found to cause sustained elimination of reactivity to cat or ragweed allergens by skin and basophil activation tests, through a mechanism thought to be mediated by inhibiting IgE-dependent basophil and mast cell activation. 42 These promising results warrant further clinical exploration.
The mechanistic target of rapamycin (mTOR) pathway is recognized to modulate the signaling of both innate and adaptive immune cells. 43 Rapamycin, the namesake inhibitor of mTOR, is approved for immunosuppression during organ transplants. While efficacious for general immunosuppression, it is possible that rapamycin could be harnessed in lower doses or locally applied doses in order to treat allergic diseases. Investigators have found that rapamycin can attenuate allergic airway inflammation in a mouse model through inhibiting eosinophil differentiation. 44 Similarly, bronchial hyper-reactivity in a guinea pig model was successfully reduced by rapamycin via inhibiting leukocyte migration. 45 Rapamycin was also able to attenuate airway hyper-reactivity, goblet cells, and IgE levels in house dust mite-induced mouse model of allergic asthma. 46 However, when compared to dexamethasone treatment in an established model of allergic asthma, a different study found that rapamycin was less potent vs steroid treatment, suggesting that it needs to be dosed before the full onset of symptoms. 47 Bortezomib is a 26S proteasome inhibitor and approved for the treatment of mantle cell lymphoma and relapsing multiple myeloma. 48 Bortezomib has also been shown to reduce the secretion of antibodies of various different classes, including IgE, by causing endoplasmic reticulum stress in plasma cells resulting in their death. 49 This property was applied to lower allergen-specific IgE levels in a mouse model of hazelnut-induced intestinal anaphylaxis, with associated improvement in clinical symptoms. 50 Thus, bortezomib could potentially reduce IgE levels similar to omalizumab. In an asthma mouse model, however, long-term bortezomib treatment was efficacious in decreasing the levels of allergen-specific IgE, but could not improve asthmatic symptoms in mice. 51 Another study found contrasting results, as bortezomib alone or in combination 52 More studies are needed to resolve this discrepancy.
A summary of repurposed drugs targeting lymphocytes is provided in Figure 1 .
| MYE LOID-MOD ULATING AGENTS
Small molecules that inhibit myeloid cells are crucial in preventing allergic disease. Indeed, antihistamines counteract the effects of mast cells, but alternative molecules that inhibit their function might have more utility. One candidate molecule is imatinib, a tyrosine kinase inhibitor that heralded the era of targeted cancer therapy by inhibiting the fusion protein, Bcr-Abl, which drives the development of chronic myelogenous leukemia (CML). 53 While traditionally described as a targeted therapy, imatinib can inhibit various tyrosine kinases, including Flt-3, Lck, and mitogen-activated protein kinase (MAPK), suppressing various functions in dendritic cells, macrophages, and T cells. 54 Imatinib can also inhibit c-Kit receptor signaling, also known as mast cell growth factor receptor, thereby causing mast cell apoptosis in cell culture. 55 Imatinib has been found to reduce T cell proliferation and activation through inhibiting T cell receptor signaling in a dose-dependent manner, an additional mechanism useful for treating allergy. 56 In a mouse model of allergic asthma induced with cockroach allergen, prior treatment with oral imatinib significantly alleviated symptoms, with decreased airway hyper-reactivity, peribronchial eosinophil accumulation, and Th2 cytokines. 57 Another supporting study discovered that imatinib can reduce airway hyper-responsiveness, smooth muscle thickening, and eosinophilic inflammation in an ovalbumin challenge-based chronic asthma mouse model. 58 Bringing these findings into human patients, studies have already found efficacy for imatinib in treating allergy and asthma. Imatinib has been shown to reverse aberrant leukotriene C4 production in neutrophils in patients with CML. 59 While promoting myelogenesis and thus cancer in CML, leukotrienes are key mediators of asthma pathogenesis being potent bronchoconstrictors and inflammatory agents. 60 Combining this information, in two patients with CML also having asthma-like lower airway symptoms, patients treated with imatinib to treat their cancer exhibited dramatic resolution of airway symptoms, suggesting targeted effects for asthma. 61 In another case report, a 42-year-old man with hypereosinophilic syndrome not responding to inhaled corticosteroid or leukotriene receptor antagonists successfully responded to imatinib treatment. 62 The efficacy from these case reports was confirmed in a randomized, doubleblind, placebo-controlled trial of 62 patients with poorly controlled severe asthma despite receiving maximal medical therapy. The patients receiving imatinib had significantly reduced airway hyperresponsiveness, mast cell counts, and tryptase release compared to patients receiving placebo. 63 Tamoxifen is a revolutionary cancer drug for patients with breast cancer, inhibiting the estrogen receptor in order to prevent tumor growth in certain types of breast cancer. 64 Interestingly, estrogen F I G U R E 1 Summary of repurposed drugs targeting lymphocytes involved in allergic disease. Lymphocytes consist of NK, B, and T cells, the latter two often implicated in allergy. Allergens recognized by the BCR or TCR can signal through BTK or ITK to activate B or T cells, but ibrutinib can inhibit this signaling. Similarly, various cytokines can activate mTOR or JAK proteins downstream of their receptors, but these signaling mechanisms can be blocked by rapamycin and tofacitinib/ruxolitinib, respectively. The production of allergic antibodies may be decreased by inhibiting with bortezomib the 26S proteasome, which normally helps degrade unfolded proteins from the ER preventing cell death. BCR, B cell receptor; TCR, T cell receptor; BTK, Bruton's tyrosine kinase; ITK, interleukin-2-inducible kinase; mTOR, mechanistic target of rapamycin; JAK1/2/3, janus kinase; ER, endoplasmic reticulum also plays a role in the development of allergy and asthma. Estrogen has been shown in a mouse model of asthma to stimulate the production of Th2 cytokines, along with regulating the action of eosinophils during allergen challenge. 65 Thus, inhibiting estrogen signaling could have benefits toward both cell types in asthma. This has been tested in vitro by demonstrating that mast cells can be inhibited by tamoxifen, limiting their proliferation and survival. 66 Similarly, tamoxifen can inhibit the maturation of dendritic cells into potent antigenpresenting cells. 67 These findings have been extended into an animal model of neutrophilic asthma, where horses treated with tamoxifen had reduced levels of bronchoalveolar lavage fluid neutrophils, comparable to dexamethasone treatment in the same animals. 68 Statins are a widely used class of medicine that lowers cholesterol levels by inhibiting HMG-CoA reductase. Some statins have also been noted to have some anti-inflammatory properties, and fluvastatin was found to be a potent suppressor of mouse mast cell activation, partly by inhibiting degranulation. 69 A retrospective cohort study did find benefits of statins for asthma patients on inhaled corticosteroids, reducing odds of hospitalization or emergency room visits by almost half. 70 However, a double-blind randomized controlled trial found that atorvastatin was not effective in reducing symptoms of persistent mild to moderate asthma. 71 Further work is needed to clarify these discrepancies. Beyond statins, other approved drugs investigated as mast cell-stabilizing drugs include nilotinib (tyrosine kinase inhibitor used in BCR-ABL-positive CML therapy), ambroxol (a mucolytic agent), and loop diuretics (eg, furosemide) and are covered in depth in the enclosed review. 72 Metformin is a commonly prescribed medication for patients with type II diabetes. It functions to suppress hepatic gluconeogenesis, but the exact molecular mechanism of action is unclear. 73 One postulated mechanism is the activation of AMP-activated protein kinase (AMPK), and metformin has been shown to decrease airway remodeling and inflammation in a chronic asthma mouse model via AMPK activation. 74 Metformin also helped protect mice from bleomycin-induced lung injury in the same study, reducing eosinophilic inflammation, peribronchial fibrosis, and smooth muscle secretion.
Given the link between asthma and obesity, 75 an extension of these findings followed obese mice on a high-fat diet that were then treated with metformin. Metformin reversed the insulin resistance in the mice, but also reduced eosinophilia in bronchoalveolar lavages upon ovalbumin challenge, demonstrating a reduction in asthmatic symptoms. 76 With these promising preclinical findings, a retrospective analysis was undertaken in order to assess, among patients with diabetes and asthma, whether metformin users were protected from asthma. Of 1332 patients with both diseases, one-third were on metformin and those patients had a lower risk of asthma exacerbation and asthma-related hospitalization, suggesting that this might be an effective treatment for this patient population. 77 This result contrasted with data evaluating metformin in a randomized controlled trial to treat patients with chronic obstructive pulmonary disease (COPD), which found that metformin had no effect on the severity of COPD exacerbations, 78 indicating that the positive effects may not extend to other lung diseases.
Pioglitazone is a PPAR-c agonist that is important in the treatment of diabetes by decreasing insulin resistance in the liver and peripheral tissues. In a preclinical study in a cockroach allergeninduced mouse model of asthma, pioglitazone was found to be just as effective as dexamethasone in reducing airway hyper-responsiveness and inflammatory cell recruitment. 79 Pioglitazone was also found to reduce NF-kappaB activity and IL-17 production in an allergic airway mouse model. 80 When these findings were translated in clinical trials, however, pioglitazone was found to have no therapeutic benefit in asthma patients in a double-blind randomized controlled trial. 81 Another randomized controlled trial testing pioglitazone to treat poorly controlled asthma in obese patients similarly revealed limited efficacy and even harm in this patient population. 82 In a randomized, double-blind, cross-over trial of patients with severe asthma resistant to inhaled corticosteroids, pioglitazone again showed no significant difference compared to steroids alone. 83 The discrepancy between mouse and human studies suggests fundamental differences in the impact of PPAR-c signaling on atopic pathways between species.
A summary of repurposed drugs targeting myeloid cells is provided in Figure 2 .
| NONIMMUNE -TARGETING AGE NTS
Endothelin-1 is important in controlling airway contraction and may also play a role in some cancers. 84 The competitive antagonist, bosentan, targets endothelin-A and endothelin-B receptors and is currently approved for treating pulmonary artery hypertension. 85 These same receptors for endothelin-1 are also important in asthma individuals. 86 However, when tested in poorly controlled asthma patients, a doubleblind, placebo-controlled, cross-over study revealed no improvement vs placebo in FEV1, b-agonist use, asthma symptom score, or asthma control test. 87 This suggests that endothelin receptor antagonism may be too far downstream in asthma pathogenesis to have a large therapeutic effect.
Vascular endothelial growth factor (VEGF) is a significant protein in the pathogenesis of asthma, with genetic polymorphisms being associated with disease development. 88 VEGF causes endothelial signaling for angiogenesis, and its levels are increased in asthma patients, contributing to increased vascularity in airway remodeling and precipitating functional abnormalities. 89 Pazopanib is an example of a small molecule that inhibits the VEGF receptor and resultant new vessel growth, which could be repurposed for asthma by inhibiting angiogenesis in the lung epithelium to alleviate symptoms and airway remodeling. 90 Pazopanib carries the added benefit of inhibiting c-Kit, 90 which is important for mast cell function and asthma pathology as discussed above. Among other drug classes investigated for asthma, the anesthetic ketamine has shown efficacy in treating intractable asthma. 91 Antioxidants eliminating reactive oxygen species (ROS) are also a potential treatment for asthma. A ROS scavenger previously studied for acute myocardial infarction therapy was identified via a drug signature analysis for repurposing to treat neutrophilic bronchial asthma.
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| 317
The antibiotic, azithromycin, has been extensively studied as an asthma therapy, with the idea that bacterial infection could worsen asthmatic symptoms and that azithromycin also has anti-inflammatory activities. 93 In a clinical trial of children aged 1-3 years, azithromycin decreased the duration of asthma-like symptoms in these pediatric patients. 93 However, a large randomized controlled trial in an adult population comparing azithromycin vs placebo to treat acute asthma exacerbations found no clinically significant benefit.
94
A placebo-controlled, randomized trial of azithromycin in preschool children was similarly ineffective in treating wheezing. 95 However, a different randomized controlled trial of 420 adults with persistent symptomatic asthma found a better quality of life with fewer exacerbations among patients treated with oral azithromycin. 96 Thus, it remains uncertain whether azithromycin is truly of benefit toward treating asthma in children and adults.
Finally, a recent postulated mechanism for the pathogenesis of asthma has opened up a common class of drugs, antifungals, for their treatment of a disease traditionally treated with immunomodulatory drugs. Many common allergens contain proteases, and these proteases have been found to cleave fibrinogen, producing proteins that act as TLR4 agonists inducing inflammation. 97 In particular, fungi can colonize the airway, secreting proteases that may perform an important role in treatment-resistant asthma patients. 98 This suggests that using common antifungal agents such as oral triazoles and inhaled amphotericin B may be a promising strategy in treating asthma, in addition to immunomodulating agents. 99 
| CONCLUSION
Drug repurposing may play a key role in allergy and asthma treatment in the future, as molecular pathways important to these diseases continue to be elucidated, opening up the use of the armament of FDA-approved drugs to target these pathways. While several candidates for drug repurposing are described in this review (summarized in Table 1 Moving forward, several key challenges remain in order to facilitate continued drug innovation in allergy and asthma. Preclinical studies and case reports will need to be verified by multiple investigators in order to ascertain their robustness. Discrepancies between the potent effects of some candidates in mouse models vs their failures in human patients will need to be illuminated further to understand predictive paradigms in allergy and asthma research. Cocktail approaches of small molecules that could provide synergies should be explored in order to maximize clinical benefit toward patients.
The costs of some specialty cancer drugs will need to decrease for allergic label indications in order for repurposing to become feasible.
Finally, it is important for the field to continue to address the root cause of allergic disorders, in addition to symptom suppression. In that regard, any small molecules that could stop the "atopic march" 100 and potentially shift immune phenotype permanently following a short-term treatment course, similar to vaccines or allergy desensitization, would rise in priority and represent a paradigm shift in the management of these patients that is not achievable with current medications.
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